A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.

HIV Infections Clinical Trial

Official title:

A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00002111
• Other study ID #: 212A
• Secondary ID: EV 14757
• Status: Completed
• Phase: Phase 1
• First received: November 2, 1999
• Last updated: June 23, 2005

Study information

• Verified date: May 1995
• Source: NIH AIDS Clinical Trials Information Service
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To investigate the toxicity, antiviral activity, and pharmacokinetics in HIV-infected patients receiving 16 weeks of oral saquinavir mesylate ( Ro 31-8959 ) at one of two doses.

Description:

Cohorts of 16 patients receive 1 of 2 doses of Ro 31-8959 for 20 weeks. Administration of the higher dose will proceed only after 2-week safety data for the first eight patients on the lower dose has been reviewed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

Patients must have:

• Documented HIV infection.

• CD4 count 200 - 500 cells/mm3.

• No evidence of viral resistance.

• HIV RNA quantifiable by PCR.

• Negativity for HBsAg, HBeAg, and anti-HBc.

NOTE:

• Fifty percent of patients must have measurable p24 antigen levels (> 31 pg/ml).

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Active opportunistic infection requiring immediate treatment, such as tuberculosis, cytomegalovirus, cerebral toxoplasmosis, and Pneumocystis carinii pneumonia.

• Unable to maintain adequate oral intake.

• Clinically significant vomiting and/or diarrhea.

• Malignancy, visceral Kaposi's sarcoma, or lymphoma that will require systemic chemotherapy within the next 12 months.

• Unable to comply with protocol requirements, in the judgment of the investigator.

• Any grade 3 or worse laboratory or clinical abnormality.

Concurrent Medication:

Excluded:

• Antineoplastic agents.

• Concomitant or maintenance treatment with excluded experimental drugs and drugs with known nephrotoxic or hepatotoxic potential.

Concurrent Treatment:

Excluded:

• Radiation therapy other than local skin radiation therapy.

Patients with the following prior conditions are excluded:

• Unexplained temperature >= 38.5 C (101.5 F) persisting for 14 days or more within a 30-day period.

• Unexplained, chronic diarrhea persisting for 14 days or more within a 30-day period.

Prior Medication:

Excluded:

• Prior treatment with an HIV proteinase inhibitor.

• AZT within 30 days prior to study entry OR lasting more than 1 year.

• Other antiretroviral therapy (besides AZT) within 30 days prior to study entry OR lasting more than 14 days.

• Acute therapy for an opportunistic infection within 14 days prior to study entry.

Study Design

Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• Saquinavir

Locations

Country	Name	City	State
United States	Stanford Univ School of Medicine	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

References & Publications (1)

Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, Merigan TC. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med. 1996 Jun 15;124(12):1039-50. — View Citation